Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions.
RTK-RNAs
Receptor tyrosine kinase
Solid tumors
circRNA
lncRNA
miRNA
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
10 Jan 2024
10 Jan 2024
Historique:
received:
28
07
2023
accepted:
27
12
2023
medline:
11
1
2024
pubmed:
11
1
2024
entrez:
10
1
2024
Statut:
epublish
Résumé
This review article presents an in-depth analysis of the current state of research on receptor tyrosine kinase regulatory non-coding RNAs (RTK-RNAs) in solid tumors. RTK-RNAs belong to a class of non-coding RNAs (nc-RNAs) responsible for regulating the expression and activity of receptor tyrosine kinases (RTKs), which play a critical role in cancer development and progression. The article explores the molecular mechanisms through which RTK-RNAs modulate RTK signaling pathways and highlights recent advancements in the field. This include the identification of potential new RTK-RNAs and development of therapeutic strategies targeting RTK-RNAs. While the review discusses promising results from a variety of studies, encompassing in vitro, in vivo, and clinical investigations, it is important to acknowledge the challenges and limitations associated with targeting RTK-RNAs for therapeutic applications. Further studies involving various cancer cell lines, animal models, and ultimately, patients are necessary to validate the efficacy of targeting RTK-RNAs. The specificity of ncRNAs in targeting cellular pathways grants them tremendous potential, but careful consideration is required to minimize off-target effects, the article additionally discusses the potential clinical applications of RTK-RNAs as biomarkers for cancer diagnosis, prognosis, and treatment. In essence, by providing a comprehensive overview of the current understanding of RTK-RNAs in solid tumors, this review emphasizes their potential as therapeutic targets for cancer while acknowledging the associated challenges and limitations.
Identifiants
pubmed: 38200584
doi: 10.1186/s12935-023-03203-2
pii: 10.1186/s12935-023-03203-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
26Informations de copyright
© 2024. The Author(s).
Références
Schlessinger JJC. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211–25.
pubmed: 11057895
doi: 10.1016/S0092-8674(00)00114-8
Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002;38:S3–10.
pubmed: 12528767
doi: 10.1016/S0959-8049(02)80597-4
Aveic S, Tonini GP. Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy? Cancer Cell Int. 2016;16:62.
pubmed: 27486382
pmcid: 4970224
doi: 10.1186/s12935-016-0341-2
Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal. 2009;2(87): re6.
pubmed: 19738203
doi: 10.1126/scisignal.287re6
Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012;12(3):197–209.
pubmed: 22268382
pmcid: 3464093
doi: 10.2174/156800912799277557
Mabeta P, Steenkamp V. The VEGF/VEGFR axis revisited: implications for cancer therapy. Int J Mol Sci. 2022;23(24):14485.
doi: 10.3390/ijms232415585
Lacal PM, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol Res. 2018;136:97–107.
pubmed: 30170190
doi: 10.1016/j.phrs.2018.08.023
Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, et al. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: a review. Int J Biol Macromol. 2022;202:539–57.
pubmed: 35074329
doi: 10.1016/j.ijbiomac.2022.01.113
Sheikh E, Tran T, Vranic S, Levy A, Bonfil RD. Role and significance of c-KIT receptor tyrosine kinase in cancer: a review. Bosn J Basic Med Sci. 2022;22(5):683–98.
pubmed: 35490363
pmcid: 9519160
Giglio S, Vecchione A. c-Met and miRs in cancer. Biomedicines. 2015;3(1):32–44.
pubmed: 28536397
pmcid: 5344231
doi: 10.3390/biomedicines3010032
Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:1–13.
doi: 10.1186/s12943-018-0782-4
Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, et al. Receptor tyrosine kinase inhibitors in cancer. Cell Mol Life Sci. 2023;80(4):104.
pubmed: 36947256
doi: 10.1007/s00018-023-04729-4
Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. PTEN function: the long and the short of it. Trends Biochem Sci. 2014;39(4):183–90.
pubmed: 24656806
pmcid: 4043120
doi: 10.1016/j.tibs.2014.02.006
Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019;179(5):1033–55.
pubmed: 31730848
pmcid: 7347159
doi: 10.1016/j.cell.2019.10.017
Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3(10):1113–21.
pubmed: 24072616
pmcid: 3801300
doi: 10.1158/2159-8290.CD-13-0202
Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, et al. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022;15(1):18.
pubmed: 35236381
pmcid: 8892735
doi: 10.1186/s13045-022-01235-1
Zeng X, Xiao J, Bai X, Liu Y, Zhang M, Liu J, et al. Research progress on the circRNA/lncRNA–miRNA–mRNA axis in gastric cancer. Pathol Res Pract. 2022;238: 154030.
pubmed: 36116329
doi: 10.1016/j.prp.2022.154030
Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA, et al. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7(1):121.
pubmed: 35418578
pmcid: 9008121
doi: 10.1038/s41392-022-00975-3
Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15(supp_1):R17–29.
pubmed: 16651366
doi: 10.1093/hmg/ddl046
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489(7414):101–8.
pubmed: 22955620
pmcid: 3684276
doi: 10.1038/nature11233
Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev. 2018;18(1):5–18.
doi: 10.1038/nrc.2017.99
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321–37.
pubmed: 29625050
pmcid: 6070353
doi: 10.1016/j.cell.2018.03.035
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.
pubmed: 8252621
doi: 10.1016/0092-8674(93)90529-Y
Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021;14(4): dmm047662.
pubmed: 33973623
pmcid: 8077553
doi: 10.1242/dmm.047662
Menigatti M, Staiano T, Manser CN, Bauerfeind P, Komljenovic A, Robinson M, et al. Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions. Oncogenesis. 2013;2(7): e56.
pubmed: 23857251
pmcid: 3740287
doi: 10.1038/oncsis.2013.21
Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui R, et al. Circulating microRNAs in cancer: potential and challenge. Front Genet. 2019;10:626.
pubmed: 31379918
pmcid: 6656856
doi: 10.3389/fgene.2019.00626
de Kock L, Rivera B, Revil T, Thorner P, Goudie C, Bouron-Dal Soglio D, et al. Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma. Br J Cancer. 2017;116(12):1621–6.
pubmed: 28524158
pmcid: 5518865
doi: 10.1038/bjc.2017.147
Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199–227.
pubmed: 18817506
pmcid: 2769253
doi: 10.1146/annurev.pathol.4.110807.092222
Donzelli S, Cioce M, Muti P, Strano S, Yarden Y, Blandino G. MicroRNAs: non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Semin Cell Dev Biol. 2016;50:133–42.
pubmed: 26773212
doi: 10.1016/j.semcdb.2015.12.020
Jiang Z, Jiang C, Yu C, Fang J. MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2. Tumour Biol. 2017;39(6):1010428317705751.
pubmed: 28618961
doi: 10.1177/1010428317705751
Tao Y, Yang S, Wu Y, Fang X, Wang Y, Song Y, et al. MicroRNA-216a inhibits the metastasis of gastric cancer cells by targeting JAK2/STAT3-mediated EMT process. Oncotarget. 2017;8(51):88870–81.
pubmed: 29179483
pmcid: 5687653
doi: 10.18632/oncotarget.21488
Li WJ, Wang Y, Liu R, Kasinski AL, Shen H, Slack FJ, et al. MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front Cell Dev Biol. 2021;9: 640587.
pubmed: 33763422
doi: 10.3389/fcell.2021.640587
Li C, Wang Y, Lu S, Zhang Z, Meng H, Liang L, et al. MiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α. Mol Med Rep. 2015;12(5):7072–8.
pubmed: 26324236
doi: 10.3892/mmr.2015.4263
Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 2011;130(2):663–79.
pubmed: 21814748
pmcid: 3381742
doi: 10.1007/s10549-011-1690-0
Wei B, Huang QY, Huang SR, Mai W, Zhong XG. MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET. Mol Med Rep. 2015;12(4):5255–61.
pubmed: 26238271
doi: 10.3892/mmr.2015.4110
Xiong R, Sun XX, Wu HR, Xu GW, Wang GX, Sun XH, et al. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance. Thorac Cancer. 2020;11(1):156–65.
pubmed: 31777195
doi: 10.1111/1759-7714.13258
Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G, et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE. 2012;7(1): e29722.
pubmed: 22235332
pmcid: 3250472
doi: 10.1371/journal.pone.0029722
Shabani N, Razaviyan J, Paryan M, Tavangar SM, Azizi F, Mohammadi-Yeganeh S, et al. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC. Hum Pathol. 2018;79:212–21.
pubmed: 29885402
doi: 10.1016/j.humpath.2018.05.019
Shabani N, Sheikholeslami S, Paryan M, Zarif Yeganeh M, Tavangar SM, Azizi F, et al. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. J Cell Physiol. 2020;235(2):1366–73.
pubmed: 31297834
doi: 10.1002/jcp.29055
Lim D, Cho JG, Yun E, Lee A, Ryu HY, Lee YJ, et al. MicroRNA 34a-AXL axis regulates vasculogenic mimicry formation in breast cancer Cells. Genes. 2020;12(1):9.
pubmed: 33374832
pmcid: 7823537
doi: 10.3390/genes12010009
Mohammady M, Ghetmiri SI, Baharizade M, Morowvat MH, Torabi S. Expanding the biotherapeutics realm via miR-34a: “potent clever little” agent in breast cancer therapy. Curr Pharm Biotechnol. 2019;20(8):665–73.
pubmed: 31244419
doi: 10.2174/1389201020666190617162042
Imani S, Zhang X, Hosseinifard H, Fu S, Fu J. The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(14):23177–87.
pubmed: 28423566
pmcid: 5410295
doi: 10.18632/oncotarget.15520
Han TY, Hou LS, Li JX, Huan ML, Zhou SY, Zhang BL. Bone targeted miRNA delivery system for miR-34a with enhanced anti-tumor efficacy to bone-associated metastatic breast cancer. Int J Pharm. 2023;635: 122755.
pubmed: 36801480
doi: 10.1016/j.ijpharm.2023.122755
Xie X, Chen Y, Chen Z, Feng Y, Wang J, Li T, et al. Polymeric hybrid nanomicelles for cancer theranostics: an efficient and precise anticancer strategy for the codelivery of doxorubicin/miR-34a and magnetic resonance Imaging. ACS Appl Mater Interfaces. 2019;11(47):43865–78.
pubmed: 31684723
doi: 10.1021/acsami.9b14908
Wang S, Cao M, Deng X, Xiao X, Yin Z, Hu Q, et al. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. Adv Healthc Mater. 2015;4(2):281–90.
pubmed: 25044638
doi: 10.1002/adhm.201400222
Zhang H, Li Y, Rao F, Liufu C, Wang Y, Chen Z. A novel UTMD system facilitating nucleic acid delivery into MDA-MB-231 cells. Biosci Rep. 2020;40(2): BSR20192573.
pubmed: 31990029
pmcid: 7029150
doi: 10.1042/BSR20192573
Wang J, Feng W, Dong Y, Mao X, Guo F, Luo F. MicroRNA-495 regulates human gastric cancer cell apoptosis and migration through Akt and mTOR signaling. Oncol Rep. 2018;40(6):3654–62.
pubmed: 30272336
Li N, Han M, Zhou N, Tang Y, Tang XS. MicroRNA-495 confers increased sensitivity to chemotherapeutic agents in gastric cancer via the mammalian target of rapamycin (mTOR) signaling pathway by interacting with human epidermal growth factor receptor 2 (ERBB2). Med Sci Monit. 2018;24:5960–72.
pubmed: 30147110
pmcid: 6122272
doi: 10.12659/MSM.909458
Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107(Pt B):2620–9.
pubmed: 29080815
doi: 10.1016/j.ijbiomac.2017.10.154
Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, et al. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 2014;35(2):1287–95.
pubmed: 24068565
doi: 10.1007/s13277-013-1171-7
Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009;284(9):5731–41.
pubmed: 19073608
doi: 10.1074/jbc.M804280200
Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS ONE. 2012;7(8): e41523.
pubmed: 22876288
pmcid: 3410899
doi: 10.1371/journal.pone.0041523
Cui YX, Bradbury R, Flamini V, Wu B, Jordan N, Jiang WG. MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells. Br J Cancer. 2017;117(1):89–101.
pubmed: 28571043
pmcid: 5563947
doi: 10.1038/bjc.2017.156
Lee KM, Choi EJ, Kim IA. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol. 2011;101(1):171–6.
pubmed: 21676478
doi: 10.1016/j.radonc.2011.05.050
Xu N, Lian YJ, Dai X, Wang YJ. miR-7 increases cisplatin sensitivity of gastric cancer cells through suppressing mTOR. Technol Cancer Res Treat. 2017;16(6):1022–30.
pubmed: 28693382
pmcid: 5762063
doi: 10.1177/1533034617717863
Zhao X, Dou W, He L, Liang S, Tie J, Liu C, et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013;32(11):1363–72.
pubmed: 22614005
doi: 10.1038/onc.2012.156
Lin J, Liu Z, Liao S, Li E, Wu X, Zeng W. Elevated microRNA-7 inhibits proliferation and tumor angiogenesis and promotes apoptosis of gastric cancer cells via repression of Raf-1. Cell Cycle. 2020;19(19):2496–508.
pubmed: 32931357
pmcid: 7553585
doi: 10.1080/15384101.2020.1807670
Expression of Concern. Elevated microRNA-7 inhibits proliferation and tumor angiogenesis and promotes apoptosis of gastric cancer cells via repression of Raf-1. Cell Cycle. 2021;20(24):2672.
doi: 10.1080/15384101.2021.1973199
Ye T, Yang M, Huang D, Wang X, Xue B, Tian N, et al. MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer. J Exp Clin Cancer Res. 2019;38(1):55.
pubmed: 30728051
pmcid: 6364399
doi: 10.1186/s13046-019-1074-6
Gu DN, Huang Q, Tian L. The molecular mechanisms and therapeutic potential of microRNA-7 in cancer. Expert Opin Ther Targets. 2015;19(3):415–26.
pubmed: 25434362
doi: 10.1517/14728222.2014.988708
Zhao JG, Men WF, Tang J. MicroRNA-7 enhances cytotoxicity induced by gefitinib in non-small cell lung cancer via inhibiting the EGFR and IGF1R signalling pathways. Contemp Oncol (Pozn). 2015;19(3):201–6.
pubmed: 26557760
Cao Q, Mao ZD, Shi YJ, Chen Y, Sun Y, Zhang Q, et al. MicroRNA-7 inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells by targeting FAK through ERK/MAPK signaling pathway. Oncotarget. 2016;7(47):77468–81.
pubmed: 27764812
pmcid: 5363598
doi: 10.18632/oncotarget.12684
Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res. 2011;17(13):4277–84.
pubmed: 21632853
doi: 10.1158/1078-0432.CCR-10-2866
Zhou N, Qu Y, Xu C, Tang Y. Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Exp Ther Med. 2016;11(2):625–30.
pubmed: 26893657
doi: 10.3892/etm.2015.2920
Chen Y, Zhou B, Xu L, Fan H, Xie J, Wang D. MicroRNA-146a promotes gastric cancer cell apoptosis by targeting transforming growth factor β-activated kinase 1. Mol Med Rep. 2017;16(1):755–63.
pubmed: 28560435
pmcid: 5482191
doi: 10.3892/mmr.2017.6640
Jiang P, Liang B, Zhang Z, Fan B, Zeng L, Zhou Z, et al. MicroRNA-146a-5p induces cell cycle arrest and enhances apoptosis in gastric cancer via targeting CDC14A. Front Cell Dev Biol. 2023;11:1181628.
pubmed: 37274736
pmcid: 10232853
doi: 10.3389/fcell.2023.1181628
Hou Z, Xie L, Yu L, Qian X, Liu B. MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis. Med Oncol. 2012;29(2):886–92.
pubmed: 21347720
doi: 10.1007/s12032-011-9862-7
Yao Q, Tu C, Lu D, Zou Y, Liu H, Zhang S. Clinicopathological significance of the microRNA-146a/WASP-family verprolin-homologous protein-2 axis in gastric cancer. Cancer Sci. 2017;108(7):1285–92.
pubmed: 28387985
pmcid: 5497796
doi: 10.1111/cas.13254
Luo Z, Li X, Zhao Z, Yang X, Xiao S, Zhou Y. MicroRNA-146a affects the chemotherapeutic sensitivity and prognosis of advanced gastric cancer through the regulation of LIN52. Oncol Lett. 2017;13(3):1386–92.
pubmed: 28454266
doi: 10.3892/ol.2016.5536
Lian S, Park JS, Xia Y, Nguyen TT, Joo YE, Kim KK, et al. MicroRNA-375 functions as a tumor-suppressor gene in gastric cancer by targeting recepteur d’Origine Nantais. Int J Mol Sci. 2016;17(10):1633.
pubmed: 27689991
pmcid: 5085666
doi: 10.3390/ijms17101633
Yan XL, Luo QY, Zhou SN, Pan WT, Zhang L, Yang DJ, et al. MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer. Clin Res Hepatol Gastroenterol. 2021;45(5): 101574.
pubmed: 33272890
doi: 10.1016/j.clinre.2020.10.015
Chen B, Guo S, Yu Z, Feng Y, Hui L. Downregulation of microRNA-375, combined with upregulation of its target gene Janus kinase 2, predicts unfavorable prognosis in patients with gastric cancer. Int J Clin Exp Pathol. 2017;10(11):11106–13.
pubmed: 31966459
pmcid: 6965865
Li Y, Jiang Q, Xia N, Yang H, Hu C. Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res. 2012;40(5):1662–9.
pubmed: 23206448
doi: 10.1177/030006051204000505
Chen LJ, Li XY, Zhao YQ, Liu WJ, Wu HJ, Liu J, et al. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance. Pathol Res Pract. 2017;213(8):882–8.
pubmed: 28688608
doi: 10.1016/j.prp.2017.06.012
Yu H, Jiang L, Sun C, Li Guo L, Lin M, Huang J, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2014;534(1):60–5.
pubmed: 24404590
doi: 10.1016/j.gene.2013.10.024
Chen WJ, Gan TQ, Qin H, Huang SN, Yang LH, Fang YY, et al. Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma. Pathol Res Pract. 2017;213(4):364–72.
pubmed: 28214218
doi: 10.1016/j.prp.2017.01.007
Ren J, Huang HJ, Gong Y, Yue S, Tang LM, Cheng SY. MicroRNA-206 suppresses gastric cancer cell growth and metastasis. Cell Biosci. 2014;4:26.
pubmed: 24855559
pmcid: 4030529
doi: 10.1186/2045-3701-4-26
Chen Z, Gao YJ, Hou RZ, Ding DY, Song DF, Wang DY, et al. MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(1):171–80.
pubmed: 31389588
Zheng Z, Yan D, Chen X, Huang H, Chen K, Li G, et al. MicroRNA-206: effective inhibition of gastric cancer progression through the c-Met pathway. PLoS ONE. 2015;10(7): e0128751.
pubmed: 26186594
pmcid: 4505964
doi: 10.1371/journal.pone.0128751
Zhou Y, Cai W, Lu H. Overexpression of microRNA-145 enhanced docetaxel sensitivity in breast cancer cells via inactivation of protein kinase B gamma-mediated phosphoinositide 3-kinase -protein kinase B pathway. Bioengineered. 2022;13(4):11310–20.
pubmed: 35499128
pmcid: 9278436
doi: 10.1080/21655979.2022.2068756
Zheng M, Sun X, Li Y, Zuo W. MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1. Tumour Biol. 2016;37(6):8189–96.
pubmed: 26715279
doi: 10.1007/s13277-015-4722-2
Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, et al. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release. 2011;155(3):427–34.
pubmed: 21723890
doi: 10.1016/j.jconrel.2011.06.026
Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Yarden Y, Domany E, Blandino G. The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. Cell Cycle. 2013;12(15):2371–5.
pubmed: 23839045
pmcid: 3841316
doi: 10.4161/cc.25380
Han M, Wang F, Gu Y, Pei X, Guo G, Yu C, et al. MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-β pathways. Oncol Rep. 2016;35(1):73–80.
pubmed: 26531758
doi: 10.3892/or.2015.4360
Fang H, Xie J, Zhang M, Zhao Z, Wan Y, Yao Y. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res. 2017;9(3):953–61.
pubmed: 28386324
pmcid: 5375989
Chen J, Wang X. MicroRNA-21 in breast cancer: diagnostic and prognostic potential. Clin Transl Oncol. 2014;16(3):225–33.
pubmed: 24248894
doi: 10.1007/s12094-013-1132-z
Lai CY, Yeh KY, Lin CY, Hsieh YW, Lai HH, Chen JR, et al. MicroRNA-21 plays multiple oncometabolic roles in the process of NAFLD-related hepatocellular carcinoma via PI3K/AKT, TGF-β, and STAT3 signaling. Cancers. 2021;13(5):940.
pubmed: 33668153
pmcid: 7956552
doi: 10.3390/cancers13050940
Bharali D, Banerjee BD, Bharadwaj M, Husain SA, Kar P. Expression analysis of microRNA-21 and microRNA-122 in hepatocellular carcinoma. J Clin Exp Hepatol. 2019;9(3):294–301.
pubmed: 31360021
doi: 10.1016/j.jceh.2018.07.005
Qu J, Yang J, Chen M, Cui L, Wang T, Gao W, et al. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: a systematic review and meta-analysis. Pak J Med Sci. 2019;35(5):1466–71.
pubmed: 31489028
pmcid: 6717466
doi: 10.12669/pjms.35.5.685
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010;411(11–12):846–52.
pubmed: 20223231
doi: 10.1016/j.cca.2010.02.074
Wang W, Li X, Liu C, Zhang X, Wu Y, Diao M, et al. MicroRNA-21 as a diagnostic and prognostic biomarker of lung cancer: a systematic review and meta-analysis. Biosci Rep. 2022;42(5):BSR0211653.
doi: 10.1042/BSR20211653
Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X, et al. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget. 2016;7(51):84508–19.
pubmed: 27811366
pmcid: 5356677
doi: 10.18632/oncotarget.13022
Xu S, Shi L. High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer. Oncol Lett. 2019;18(1):758–63.
pubmed: 31289551
pmcid: 6539534
Shao C, Yang F, Qin Z, Jing X, Shu Y, Shen H. The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis. BMC Cancer. 2019;19(1):1103.
pubmed: 31727002
pmcid: 6854776
doi: 10.1186/s12885-019-6297-6
Wang J, Wang Q, Guan Y, Sun Y, Wang X, Lively K, et al. Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. J Clin Investag. 2022;132(19): e157248.
doi: 10.1172/JCI157248
Zhang G, Zhong L, Luo H, Wang S. MicroRNA-155-3p promotes breast cancer progression through down-regulating CADM1. Onco Targets Ther. 2019;12:7993–8002.
pubmed: 31579252
pmcid: 6773971
doi: 10.2147/OTT.S206180
Hosseini Mojahed F, Aalami AH, Pouresmaeil V, Amirabadi A, Qasemi Rad M, Sahebkar A. Clinical evaluation of the diagnostic role of microRNA-155 in breast cancer. Int J Genomics. 2020;2020:9514831.
pubmed: 32964011
pmcid: 7495225
doi: 10.1155/2020/9514831
Li D, Liu X, Lin L, Hou J, Li N, Wang C, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 2011;286(42):36677–85.
pubmed: 21878637
pmcid: 3196113
doi: 10.1074/jbc.M111.270561
Ning S, Liu H, Gao B, Wei W, Yang A, Li J, et al. miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma. Oncol Lett. 2019;18(3):3381–7.
pubmed: 31452818
pmcid: 6676662
Cai C, Xie Y, Wu L, Chen X, Liu H, Zhou Y, et al. PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma. Sci Rep. 2017;7:46250.
pubmed: 28387375
pmcid: 5384185
doi: 10.1038/srep46250
Sheng L, He P, Yang X, Zhou M, Feng Q. miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2. Cell Death Dis. 2015;6(7): e1808.
pubmed: 26158514
pmcid: 4650731
doi: 10.1038/cddis.2015.184
Zhu SH, He XC, Wang L. Correlation analysis of miR-200b, miR-200c, and miR-141 with liver metastases in colorectal cancer patients. Eur Rev Med Pharmacol Sci. 2017;21(10):2357–63.
pubmed: 28617555
Chen X, Zeng K, Xu M, Liu X, Hu X, Xu T, et al. P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2. Cell Death Dis. 2019;10(2):131.
pubmed: 30755600
pmcid: 6372610
doi: 10.1038/s41419-018-1188-3
Zhou Q, Zhu Y, Wei X, Zhou J, Chang L, Sui H, et al. MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis. Cell Death Dis. 2016;7(10): e2413.
pubmed: 27735951
pmcid: 5133975
doi: 10.1038/cddis.2016.306
Xu Z, Zhu C, Chen C, Zong Y, Feng H, Liu D, et al. CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer. Cell Death Dis. 2018;9(10):974.
pubmed: 30250188
pmcid: 6155262
doi: 10.1038/s41419-018-1010-2
Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9(1):5395.
pubmed: 30568162
pmcid: 6300604
doi: 10.1038/s41467-018-07810-w
Qian X, Yu J, Yin Y, He J, Wang L, Li Q, et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 2013;12(9):1385–94.
pubmed: 23574723
pmcid: 3674066
doi: 10.4161/cc.24477
Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 2013;30(4):1976–84.
pubmed: 23900443
doi: 10.3892/or.2013.2633
Tsang WP, Kwok TT. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 2009;30(6):953–9.
pubmed: 19372139
doi: 10.1093/carcin/bgp094
Han HB, Gu J, Zuo HJ, Chen ZG, Zhao W, Li M, et al. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol. 2012;226(3):544–55.
pubmed: 21984339
doi: 10.1002/path.3014
Wang MJ, Li Y, Wang R, Wang C, Yu YY, Yang L, et al. Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer. Int J Colorectal Dis. 2013;28(2):183–9.
pubmed: 22885837
doi: 10.1007/s00384-012-1550-3
Zhang Z, Wang J, Cheng J, Yu X. Effects of miR-126 on the STAT3 signaling pathway and the regulation of malignant behavior in lung cancer cells. Oncol Lett. 2018;15(6):8412–6.
pubmed: 29805576
pmcid: 5950602
Shi H, Bi H, Sun X, Dong H, Jiang Y, Mu H, et al. Antitumor effects of tubeimoside-1 in NCI-H1299 cells are mediated by microRNA-126-5p-induced inactivation of VEGF-A/VEGFR-2/ERK signaling pathway. Mol Med Rep. 2018;17(3):4327–36.
pubmed: 29363720
pmcid: 5802206
Jia Z, Zhang Y, Xu Q, Guo W, Guo A. miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/Snail signaling of lung cancer cells. Oncol Lett. 2018;15(5):7369–75.
pubmed: 29725450
pmcid: 5920360
Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261–71.
pubmed: 18694565
pmcid: 2685763
doi: 10.1016/j.devcel.2008.07.002
Hou L, Luo P, Ma Y, Jia C, Yu F, Lv Z, et al. MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 2017;14(4):4441–8.
pubmed: 29085440
pmcid: 5649526
doi: 10.3892/ol.2017.6809
Huang H, Huang J, Yao J, Li N, Yang Z. miR-125a regulates HAS1 and inhibits the proliferation, invasion and metastasis by targeting STAT3 in non-small cell lung cancer cells. J Cell Biochem. 2020;121(5–6):3197–207.
pubmed: 31930562
doi: 10.1002/jcb.29586
Yagishita S, Fujita Y, Kitazono S, Ko R, Nakadate Y, Sawada T, et al. Chemotherapy-regulated microRNA-125-HER2 pathway as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in small cell lung cancer. Mol Cancer Ther. 2015;14(6):1414–23.
pubmed: 25833836
doi: 10.1158/1535-7163.MCT-14-0625
Khan P, Ebenezer NS, Siddiqui JA, Maurya SK, Lakshmanan I, Salgia R, et al. MicroRNA-1: diverse role of a small player in multiple cancers. Semin Cell Dev Biol. 2022;124:114–26.
pubmed: 34034986
doi: 10.1016/j.semcdb.2021.05.020
Qu W, Chen X, Wang J, Lv J, Yan D. MicroRNA-1 inhibits ovarian cancer cell proliferation and migration through c-Met pathway. Clin Chim Acta. 2017;473:237–44.
pubmed: 28698064
doi: 10.1016/j.cca.2017.07.008
Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 2012;18(3):737–47.
pubmed: 22179665
doi: 10.1158/1078-0432.CCR-11-1699
Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res. 2012;10(4):504–15.
pubmed: 22343615
doi: 10.1158/1541-7786.MCR-11-0342
Jiang S, Zhao C, Yang X, Li X, Pan Q, Huang H, et al. miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression. Int J Mol Med. 2016;38(1):113–22.
pubmed: 27247259
pmcid: 4899011
doi: 10.3892/ijmm.2016.2619
Koshizuka K, Hanazawa T, Fukumoto I, Kikkawa N, Matsushita R, Mataki H, et al. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. J Hum Genet. 2017;62(1):113–21.
pubmed: 27169691
doi: 10.1038/jhg.2016.47
Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, et al. miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol. 2013;42(2):667–75.
pubmed: 23229283
doi: 10.3892/ijo.2012.1717
Chang YS, Chen WY, Yin JJ, Sheppard-Tillman H, Huang J, Liu YN. EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res. 2015;75(15):3077–86.
pubmed: 26071255
pmcid: 4909124
doi: 10.1158/0008-5472.CAN-14-3380
Chiu KL, Lin YS, Kuo TT, Lo CC, Huang YK, Chang HF, et al. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. Oncotarget. 2017;8(29):47365–78.
pubmed: 28537886
pmcid: 5564571
doi: 10.18632/oncotarget.17648
Han C, Zhou Y, An Q, Li F, Li D, Zhang X, et al. MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. Tumour Biol. 2015;36(9):6715–23.
pubmed: 25874496
doi: 10.1007/s13277-015-3358-6
Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem. 2009;284(43):29596–604.
pubmed: 19710019
pmcid: 2785592
doi: 10.1074/jbc.M109.020511
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.
pubmed: 30970190
doi: 10.1056/NEJMra1713263
Baboci L, Capolla S, Di Cintio F, Colombo F, Mauro P, Dal Bo M, et al. The dual role of the liver in nanomedicine as an actor in the elimination of nanostructures or a therapeutic target. J Oncol. 2020;2020:4638192.
pubmed: 32184825
pmcid: 7060440
doi: 10.1155/2020/4638192
Alehossein P, Taheri M, Tayefeh Ghahremani P, Dakhlallah D, Brown CM, Ishrat T, et al. Transplantation of exercise-induced extracellular vesicles as a promising therapeutic approach in ischemic stroke. Transl Stroke Res. 2023;14(2):211–37.
pubmed: 35596116
doi: 10.1007/s12975-022-01025-4
Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C-G, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Can Res. 2007;67(13):6092–9.
doi: 10.1158/0008-5472.CAN-06-4607
Tsai W-C, Hsu PW-C, Lai T-C, Chau G-Y, Lin C-W, Chen C-M, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009;49(5):1571–82.
pubmed: 19296470
doi: 10.1002/hep.22806
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.
pubmed: 17681183
doi: 10.1053/j.gastro.2007.05.022
Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14(2):419–27.
pubmed: 18223217
pmcid: 2755230
doi: 10.1158/1078-0432.CCR-07-0523
Panebianco F, Climent M, Malvindi MA, Pompa PP, Bonetti P, Nicassio F. Delivery of biologically active miR-34a in normal and cancer mammary epithelial cells by synthetic nanoparticles. Nanomed Nanotechnol Biol Med. 2019;19:95–105.
doi: 10.1016/j.nano.2019.03.013
Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Can Res. 2010;70(14):5923–30.
doi: 10.1158/0008-5472.CAN-10-0655
Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2015;34(27):3547–55.
pubmed: 25174400
doi: 10.1038/onc.2014.282
Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014;22(8):1494–503.
pubmed: 24791940
pmcid: 4435581
doi: 10.1038/mt.2014.79
Beg MS, Brenner AJ, Sachdev J, Borad M, Kang Y-K, Stoudemire J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35:180–8.
pubmed: 27917453
doi: 10.1007/s10637-016-0407-y
Hong DS, Kang Y-K, Borad M, Sachdev J, Ejadi S, Lim HY, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630–7.
pubmed: 32238921
pmcid: 7251107
doi: 10.1038/s41416-020-0802-1
Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, et al. Therapeutic delivery of MicroRNA-29b by cationic lipoplexes for lung cancer. Mol Ther Nucleic Acids. 2013;2(4): e84.
pubmed: 23591808
pmcid: 3650246
doi: 10.1038/mtna.2013.14
van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386–96.
pubmed: 28870611
doi: 10.1016/S1470-2045(17)30621-6
Hsieh TH, Hsu CY, Tsai CF, Long CY, Chai CY, Hou MF, et al. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget. 2015;6(1):494–509.
pubmed: 25504437
doi: 10.18632/oncotarget.2674
Hayward SL, Francis DM, Kholmatov P, Kidambi S. Targeted delivery of microRNA125a-5p by engineered lipid nanoparticles for the treatment of HER2 positive metastatic breast cancer. J Biomed Nanotechnol. 2016;12(3):554–68.
pubmed: 27280253
doi: 10.1166/jbn.2016.2194
Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014;35(14):4333–44.
pubmed: 24565525
doi: 10.1016/j.biomaterials.2014.02.006
Imani S, Wu R-C, Fu J. MicroRNA-34 family in breast cancer: from research to therapeutic potential. J Cancer. 2018;9(20):3765.
pubmed: 30405848
pmcid: 6216011
doi: 10.7150/jca.25576
Zhi F, Dong H, Jia X, Guo W, Lu H, Yang Y, et al. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS ONE. 2013;8(3): e60034.
pubmed: 23527297
pmcid: 3603917
doi: 10.1371/journal.pone.0060034
Yu Y, Yao Y, Yan H, Wang R, Zhang Z, Sun X, et al. A tumor-specific microRNA recognition system facilitates the accurate targeting to tumor cells by magnetic nanoparticles. Mol Ther Nucleic Acids. 2016;5(5): e318.
pubmed: 27138178
pmcid: 5014513
doi: 10.1038/mtna.2016.28
Kim HK, Fuchs G, Wang S, Wei W, Zhang Y, Park H, et al. A transfer-RNA-derived small RNA regulates ribosome biogenesis. Nature. 2017;552(7683):57–62.
pubmed: 29186115
pmcid: 6066594
doi: 10.1038/nature25005
Iwasaki YW, Siomi MC, Siomi H. PIWI-interacting RNA: its biogenesis and functions. Annu Rev Biochem. 2015;84:405–33.
pubmed: 25747396
doi: 10.1146/annurev-biochem-060614-034258
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.
pubmed: 11252954
doi: 10.1038/35052073
Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145–66.
pubmed: 22663078
doi: 10.1146/annurev-biochem-051410-092902
Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.
pubmed: 26666209
doi: 10.1038/nrg.2015.10
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.
pubmed: 19182780
pmcid: 2754849
doi: 10.1038/nature07672
Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26–46.
pubmed: 23827673
pmcid: 3924787
doi: 10.1016/j.cell.2013.06.020
Hong Q, Li O, Zheng W, Xiao W-Z, Zhang L, Wu D, et al. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma. Cell Death Dis. 2017;8(5): e2772.
pubmed: 28492542
pmcid: 5520706
doi: 10.1038/cddis.2017.181
Li Q, Wang X, Jiang N, Xie X, Liu N, Liu J, et al. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma. Cancer Med. 2020;9(17):6354–66.
pubmed: 32673448
pmcid: 7476833
doi: 10.1002/cam4.3303
Yu X, Lin Q, Liu F, Yang F, Mao J, Chen X. LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p. Int J Immunopathol Pharmacol. 2020;34:2058738420958947.
pubmed: 32969763
pmcid: 7520928
doi: 10.1177/2058738420958947
Zhang H, Liao Z, Liu F, Su C, Zhu H, Li Y, et al. Long noncoding RNA HULC promotes hepatocellular carcinoma progression. Aging (Albany NY). 2019;11(20):9111.
pubmed: 31645479
doi: 10.18632/aging.102378
Yang L, Cao M, Zhang J, Li X, Sun Q. LncRNA XIST modulates HIF-1A/AXL signaling pathway by inhibiting miR-93-5p in colorectal cancer. Mol Genet Genomic Med. 2020;8(4): e1112.
pubmed: 32061057
pmcid: 7196477
doi: 10.1002/mgg3.1112
Zhang R, Wang Z, Yu Q, Shen J, He W, Zhou D, et al. Atractylenolide II reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells. J Cell Mol Med. 2019;23(5):3151–65.
pubmed: 30907503
pmcid: 6484310
doi: 10.1111/jcmm.14148
Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther. 2016;24(12):2064–77.
pubmed: 27633443
pmcid: 5167786
doi: 10.1038/mt.2016.180
Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015;6(30):29209.
pubmed: 26353930
pmcid: 4745721
doi: 10.18632/oncotarget.4976
Bi S, Wang C, Li Y, Zhang W, Zhang J, Lv Z, et al. LncRNA-MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma. Tumor Biol. 2017;39(5):1010428317699796.
doi: 10.1177/1010428317699796
Kawasaki Y, Miyamoto M, Oda T, Matsumura K, Negishi L, Nakato R, et al. The novel lnc RNA CALIC upregulates AXL to promote colon cancer metastasis. EMBO Rep. 2019;20(8): e47052.
pubmed: 31353791
pmcid: 6680119
doi: 10.15252/embr.201847052
Samimi H, Haghpanah V, Irani S, Arefian E, Sohi AN, Fallah P, et al. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor “BI-847325” on anaplastic thyroid carcinoma. DARU J Pharm Sci. 2019;27:1–7.
doi: 10.1007/s40199-018-0231-3
Li C, Wang S, Xing Z, Lin A, Liang K, Song J, et al. A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017;19(2):106–19.
pubmed: 28114269
pmcid: 5336186
doi: 10.1038/ncb3464
Drak Alsibai K, Meseure D. Tumor microenvironment and noncoding RNAs as co-drivers of epithelial–mesenchymal transition and cancer metastasis. Dev Dyn. 2018;247(3):405–31.
pubmed: 28691356
doi: 10.1002/dvdy.24548
Yan J, Xu C, Li Y, Tang B, Xie S, Hong T, et al. Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL. J Cell Mol Med. 2019;23(8):5518–31.
pubmed: 31240814
pmcid: 6653591
doi: 10.1111/jcmm.14435
Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, et al. LIMT is a novel metastasis inhibiting lnc RNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Mol Med. 2016;8(9):1052–64.
pubmed: 27485121
pmcid: 5009810
doi: 10.15252/emmm.201606198
Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Molecular cancer. 2020;19:1–8. https://doi.org/10.1186/s12943-020-01188-4 .
Wang Y, Liu Z, Yao B, Dou C, Xu M, Xue Y, et al. Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma. Tumor Biol. 2016;37:11429–41.
doi: 10.1007/s13277-016-4892-6
Ding D, Zhang J, Luo Z, Wu H, Lin Z, Liang W, et al. Analysis of the lncRNA–miRNA–mRNA network reveals a potential regulatory mechanism of EGFR-TKI resistance in NSCLC. Front Genet. 2022;13: 851391.
pubmed: 35571024
pmcid: 9099042
doi: 10.3389/fgene.2022.851391
Si J, Ma Y, Lv C, Hong Y, Tan H, Yang Y. HIF1A-AS2 induces osimertinib resistance in lung adenocarcinoma patients by regulating the miR-146b-5p/IL-6/STAT3 axis. Mol Ther Nucleic Acids. 2021;26:613–24.
pubmed: 34703647
pmcid: 8517096
doi: 10.1016/j.omtn.2021.09.003
Dong S, Qu X, Li W, Zhong X, Li P, Yang S, et al. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. J Hematol Oncol. 2015;8(1):1–13.
doi: 10.1186/s13045-015-0140-6
Lv P, Yang S, Liu W, Qin H, Tang X, Wu F, et al. Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Thorac Cancer. 2020;11(1):29–40.
pubmed: 31691525
doi: 10.1111/1759-7714.13216
Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H, et al. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget. 2015;6(27):23582.
pubmed: 26160838
pmcid: 4695138
doi: 10.18632/oncotarget.4361
Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, et al. Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling. Int J Mol Sci. 2021;22(8):4005.
pubmed: 33924522
pmcid: 8070547
doi: 10.3390/ijms22084005
Wang S, Liu C, Lei Q, Wu Z, Miao X, Zhu D, et al. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells. Respir Res. 2021;22(1):1–10.
pubmed: 33407436
pmcid: 7789396
doi: 10.1186/s12931-021-01719-7
Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, et al. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor (AR)/miRNA-143-3p signals. Cell Death Differ. 2017;24(9):1502–17.
pubmed: 28644440
pmcid: 5563985
doi: 10.1038/cdd.2017.74
Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–57.
pubmed: 23249747
pmcid: 3543092
doi: 10.1261/rna.035667.112
Li X, Liu C-X, Xue W, Zhang Y, Jiang S, Yin Q-F, et al. Coordinated circRNA biogenesis and function with NF90/NF110 in viral infection. Mol Cell. 2017;67(2):214–27.
pubmed: 28625552
doi: 10.1016/j.molcel.2017.05.023
Chen L-L, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12(4):381–8.
pubmed: 25746834
pmcid: 4615371
doi: 10.1080/15476286.2015.1020271
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.
pubmed: 23446346
doi: 10.1038/nature11993
Chen Y, Wu Y. Hsa_circ_0070661 inhibits cancer progression through miR-556–5p/TEK axis in lung adenocarcinoma. Cancer Biomark. 2023;37:1–13.
pubmed: 36938724
doi: 10.3233/CBM-230209
Li W, Wang H, Zheng Y. Circ_0001058 represses the progression of lung adenocarcinoma through governing of the miR-486-5p/TEK signaling axis. Anticancer Drugs. 2022;33(8):710–9.
pubmed: 35946541
doi: 10.1097/CAD.0000000000001337
Wang X, Zhu X, Zhang H, Wei S, Chen Y, Chen Y, et al. Increased circular RNA hsa_circ_0012673 acts as a sponge of miR-22 to promote lung adenocarcinoma proliferation. Biochem Biophys Res Commun. 2018;496(4):1069–75.
pubmed: 29366790
doi: 10.1016/j.bbrc.2018.01.126
Pei J, Dou H, Deng X. CircFAM53B promotes the proliferation and metastasis of glioma through activating the c-MET/PI3K/AKT pathway via sponging miR-532-3p. Cell Cycle. 2022;21(5):462–76.
pubmed: 35100091
pmcid: 8942547
doi: 10.1080/15384101.2021.2014738
Wang J, Li J, Duan P, Dang Y, Shi T. Circ_0001588 upregulates erbb4 to promote glioma malignant progression through sponging mir-1281. Neurotox Res. 2022;89:1–14.
Zhou D, Lin X, Wang P, Yang Y, Zheng J, Zhou D. Circular RNA circ_0001162 promotes cell proliferation and invasion of glioma via the miR-936/ERBB4 axis. Bioengineered. 2021;12(1):2106–18.
pubmed: 34057019
pmcid: 8806513
doi: 10.1080/21655979.2021.1932221
Jin C, Zhao J, Zhang ZP, Wu M, Li J, Liu B, et al. CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10. Mol Oncol. 2021;15(2):596–622.
pubmed: 33085838
doi: 10.1002/1878-0261.12830
Yang H, Yu G, Wang Y, Guo X. Circ_0044520 regulates the progression of laryngeal squamous cell carcinoma via the miR-338–3p/ROR2 axis. Histol Histopathol. 2022;37(6):513–26.
pubmed: 35037694
Yejia C, Jin C, Huang S, Jinjun Y, Huang H, Dan L, et al. circRNA_0006470 promotes the proliferation and migration of gastric cancer cells by functioning as a sponge of miR-27b-3p. Neoplasma. 2021;68(6):1245.
doi: 10.4149/neo_2021_210222N235
Yang B, Teng F, Chang L, Wang J, Liu D-L, Cui Y-S, et al. Tumor-derived exosomal circRNA_102481 contributes to EGFR-TKIs resistance via the miR-30a-5p/ROR1 axis in non-small cell lung cancer. Aging (Albany NY). 2021;13(9):13264.
pubmed: 33952725
doi: 10.18632/aging.203011
Chen LY, Zhi Z, Wang L, Zhao YY, Deng M, Liu YH, et al. NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling. J Pathol. 2019;248(1):103–15.
pubmed: 30666650
doi: 10.1002/path.5238
Zheng H, Fu Q, Ma K, Shi S, Fu Y. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling. Endocr J. 2021;68(11):1247–66.
pubmed: 34565758
doi: 10.1507/endocrj.EJ20-0498
Wang S, Li Z, Zhu G, Hong L, Hu C, Wang K, et al. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis. J Ovarian Res. 2021;14:1–17.
doi: 10.1186/s13048-021-00917-7
Deng L, Liu G, Zheng C, Zhang L, Kang Y, Yang F. Circ-LAMP1 promotes T-cell lymphoblastic lymphoma progression via acting as a ceRNA for miR-615-5p to regulate DDR2 expression. Gene. 2019;701:146–51.
pubmed: 30922709
doi: 10.1016/j.gene.2019.03.052
Dai C, Ma Z, Si J, An G, Zhang W, Li S, et al. Hsa_circ_0007312 promotes third-generation epidermal growth factor receptor-tyrosine kinase inhibitor resistance through pyroptosis and apoptosis via the MiR-764/MAPK1 axis in lung adenocarcinoma cells. J Cancer. 2022;13(9):2798.
pubmed: 35812182
pmcid: 9254875
doi: 10.7150/jca.72066
Niu R, Li D, Chen J, Zhao W. Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway. Cell Cycle. 2022;21(1):86–100.
pubmed: 34919024
doi: 10.1080/15384101.2021.2009986
Liu S, Jiang Z, Xiao P, Li X, Chen Y, Tang H, et al. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells. Cancer Sci. 2022;113(1):79–90.
pubmed: 34706132
doi: 10.1111/cas.15177
Gao J, Ding C, Zhou J, Wu G, Han Z, Li J, et al. Propofol suppresses lung cancer tumorigenesis by modulating the circ-ERBB2/miR-7-5p/FOXM1 axis. Thorac Cancer. 2021;12(6):824–34.
pubmed: 33506582
pmcid: 7952809
doi: 10.1111/1759-7714.13856
Liu Y-T, Han X-H, Xing P-Y, Hu X-S, Hao X-Z, Wang Y, et al. Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer. J Thorac Dis. 2019;11(5):1779.
pubmed: 31285870
pmcid: 6588778
doi: 10.21037/jtd.2019.05.22
Wang T, Liu Z, She Y, Deng J, Zhong Y, Zhao M, et al. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. Cancer Lett. 2021;520:321–31.
pubmed: 34389432
doi: 10.1016/j.canlet.2021.08.007
Tan L, Huang Z, Chen Z, Chen S, Ye Y, Chen T, et al. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair. J Chemother. 2023;35(1):11–8.
pubmed: 34927575
doi: 10.1080/1120009X.2021.2009990
Hüttenhofer A, Vogel J. Experimental approaches to identify non-coding RNAs. Nucleic Acids Res. 2006;34(2):635–46.
pubmed: 16436800
pmcid: 1351373
doi: 10.1093/nar/gkj469
Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57(1):84–91.
pubmed: 21036945
doi: 10.1373/clinchem.2010.151845
Yang G, Wu D, Zhu J, Jiang O, Shi Q, Tian J, et al. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep. 2013;30(2):877–89.
pubmed: 23760062
doi: 10.3892/or.2013.2532
Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG, Ge SL, et al. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer. Mol Biol Rep. 2014;41(9):5913–22.
pubmed: 25103018
doi: 10.1007/s11033-014-3466-1
Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE. 2012;7(10): e47003.
pubmed: 23071695
pmcid: 3468565
doi: 10.1371/journal.pone.0047003
Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013;34(4):2175–81.
pubmed: 23625654
doi: 10.1007/s13277-013-0753-8
Jiang M, Li X, Quan X, Li X, Zhou B. MiR-92a family: a novel diagnostic biomarker and potential therapeutic target in human cancers. Front Mol Biosci. 2019;6:98.
pubmed: 31632984
pmcid: 6779690
doi: 10.3389/fmolb.2019.00098
Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259(4):735–43.
pubmed: 23982750
doi: 10.1097/SLA.0b013e3182a6909d
Zuo Z, Li Y, Zeng C, Xi Y, Tao H, Guo Y. Integrated analyses identify key molecules and reveal the potential mechanism of miR-182-5p/FOXO1 axis in alcoholic liver disease. Front Med. 2021;8: 767584.
doi: 10.3389/fmed.2021.767584
Soliman SE, Elabd NS, El-Kousy SM, Awad MF. Down regulation of miR-30a-5p and miR-182-5p in gastric cancer: clinical impact and survival analysis. Biochem Biophys Rep. 2021;27: 101079.
pubmed: 34355069
pmcid: 8321916
Wu J, Li G, Wang Z, Yao Y, Chen R, Pu X, et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer. Dis Markers. 2015;2015: 435656.
pubmed: 26063956
pmcid: 4433679
doi: 10.1155/2015/435656
Peng Q, Shen Y, Lin K, Zou L, Shen Y, Zhu Y. Comprehensive and integrative analysis identifies microRNA-106 as a novel non-invasive biomarker for detection of gastric cancer. J Transl Med. 2018;16(1):127.
pubmed: 29764446
pmcid: 5952699
doi: 10.1186/s12967-018-1510-y
Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol. 2013;30(1):452.
pubmed: 23307259
doi: 10.1007/s12032-012-0452-0
Farasati Far B, Vakili K, Fathi M, Yaghoobpoor S, Bhia M, Naimi-Jamal MR. The role of microRNA-21 (miR-21) in pathogenesis, diagnosis, and prognosis of gastrointestinal cancers: a review. Life Sci. 2023;316: 121340.
pubmed: 36586571
doi: 10.1016/j.lfs.2022.121340
Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009;2(9):807–13.
pubmed: 19723895
doi: 10.1158/1940-6207.CAPR-09-0094
Xia J, Cao T, Ma C, Shi Y, Sun Y, Wang ZP, et al. miR-7 suppresses tumor progression by directly targeting MAP3K9 in pancreatic cancer. Mol Ther Nucleic Acids. 2018;13:121–32.
pubmed: 30290304
pmcid: 6171162
doi: 10.1016/j.omtn.2018.08.012
Ye ZQ, Zou CL, Chen HB, Jiang MJ, Mei Z, Gu DN. MicroRNA-7 as a potential biomarker for prognosis in pancreatic cancer. Dis Markers. 2020;2020:2782101.
pubmed: 32566037
pmcid: 7288197
doi: 10.1155/2020/2782101
Paik WH, Song BJ, Kim HW, Kim HR, Hwang JH. MicroRNA-200c as a prognostic biomarker for pancreatic cancer. Korean J Gastroenterol. 2015;66(4):215–20.
pubmed: 26493507
doi: 10.4166/kjg.2015.66.4.215
Dong L, Hou X, Liu F, Tao H, Zhang Y, Zhao H, et al. Regulation of insulin resistance by targeting the insulin-like growth factor 1 receptor with microRNA-122-5p in hepatic cells. Cell Biol Int. 2019;43(5):553–64.
pubmed: 30958584
doi: 10.1002/cbin.11129
Dai M, Li L, Qin X. Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer. Oncol Lett. 2019;17(4):3919–29.
pubmed: 30881509
pmcid: 6403504
Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56(1):167–75.
pubmed: 21749846
doi: 10.1016/j.jhep.2011.04.026
Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 2015;36(4):3035–42.
pubmed: 25501703
doi: 10.1007/s13277-014-2938-1
Grimolizzi F, Monaco F, Leoni F, Bracci M, Staffolani S, Bersaglieri C, et al. Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression. Sci Rep. 2017;7(1):15277.
pubmed: 29127370
pmcid: 5681649
doi: 10.1038/s41598-017-15475-6
Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS ONE. 2016;11(4): e0153046.
pubmed: 27093275
pmcid: 4836744
doi: 10.1371/journal.pone.0153046
Hou B, Ishinaga H, Midorikawa K, Nakamura S, Hiraku Y, Oikawa S, et al. Let-7c inhibits migration and epithelial-mesenchymal transition in head and neck squamous cell carcinoma by targeting IGF1R and HMGA2. Oncotarget. 2018;9(10):8927–40.
pubmed: 29507664
pmcid: 5823619
doi: 10.18632/oncotarget.23826
Dou H, Wang Y, Su G, Zhao S. Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. Int J Clin Exp Med. 2015;8(6):9291–8.
pubmed: 26309587
pmcid: 4538081
Huang Y-F, Zhang Y, Fu X. Long non-coding RNA DANCR promoted non-small cell lung cancer cells metastasis via modulating of miR-1225–3p/ErbB2 signal. Eur Rev Med Pharm Sci. 2021;25(2):758–69.
Du Y, Chen Y, Wu T, Fan X, Lin W, Jiang Z. miR-2682-3p antagonizes its host lncRNA-MIR137HG by interacting with the same target FUS to regulate the progression of gastric cancer. BMC Cancer. 2022;22(1):1–15.
Han X, Jia Y, Chen X, Sun C, Sun J. lncRNA TINCR attenuates the proliferation and invasion, and enhances the apoptosis of cutaneous malignant melanoma cells by regulating the miR-424-5p/LATS1 axis. Oncol Rep. 2021;46(5):1–11.
doi: 10.3892/or.2021.8189
Wen L, Zheng Y, Wen X, Zhang Y, Zeng W. Increased expression of long noncoding RNA GAS6-AS2 promotes proliferation and inhibits apoptosis of melanoma cells via upregulating GAS6 expression. IUBMB Life. 2019;71(10):1503–14.
pubmed: 31162889
doi: 10.1002/iub.2071
Dai C, Liu B, Li S, Hong Y, Si J, Xiong Y, et al. Construction of a circRNA-miRNA-mRNA regulated pathway involved in EGFR-TKI lung adenocarcinoma resistance. Technol Cancer Res Treat. 2021;20:15330338211056808.
pubmed: 34825849
pmcid: 8647233
doi: 10.1177/15330338211056809